April 28, 2021 -- Preclinical data suggest positive results from a COVID-19 vaccine candidate based on enveloped viruslike particle (eVLP) technology from VBI Vaccines (VBI).
Candidate VBI-2902 expressed a modified, prefusion form of the SARS-CoV-2 spike protein that elicited a highly potent and focused neutralizing antibody response and conferred a protective benefit in Syrian golden hamsters that had COVID-19. This was assessed in terms of clinical disease, such as loss of body weight and lung inflammation. Also, the vaccine candidate showed potential to be highly effective after a single dose, according to the data.
Copyright © 2021 scienceboard.net